Euticals S.p.A.

Fineurop Soditic acted as exclusive financial advisor to Euticals’ shareholders in the sale of a majority stake of the Company to Mandarin Capital Partners, the largest Chinese-Italian private equity fund, in a leveraged management buy out transaction, for a total consideration of around Euro 70 million. Euticals, based in Lodi, is a leading chemical pharmaceutical company involved in the development and production of intermediates and active pharmaceutical ingredients with different production technologies. Euticals reported annual revenues of Euro 50 million, with an Ebitda of Euro 10 million. Mandarin Capital will support Euticals’ strategy aiming to double the Company’s turnover in the next 3-4 years also through add on acquisitions of Chinese companies active in the chemical- pharmaceutical business.